Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/multi-targeted-therapies-in-non-small-cell-lung-cancer-KT8P0CEBlU
References (38)
-
T. Stinchcombe, M. Socinski (2009)
Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of TherapyJournal of Thoracic Oncology, 4
-
A.A. Adjei, S. Mandrekar, R.S. Marks (2005)
A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent nonsmall-cell lung cancerProcAm Soc Clin Oncol, 23
-
C. Gridelli, A. Rossi, P. Maione (2003)
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agentsOncogene, 22
-
T. Abrams, Leslie Lee, Lesley Murray, N. Pryer, J. Cherrington (2003)
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.Molecular cancer therapeutics, 2 5
-
D. Carney (2002)
Lung cancer--time to move on from chemotherapy.The New England journal of medicine, 346 2
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, David Forman (2011)
Global Cancer Statistics -
L. Tanoue (2007)
Erlotinib in Previously Treated Non-Small-Cell Lung CancerYearbook of Pulmonary Disease, 2007
-
S. Yano, Y. Nishioka, H. Goto, S. Sone (2003)
Molecular mechanisms of angiogenesis in non‐small cell lung cancer, and therapeutics targeting related moleculesCancer Science, 94
-
D.B. Mendel, A.D. Laird, X. Xin (2003)
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors: determination of pharmacokinetic/pharmaco dynamic relationshipClin Cancer Res, 9
-
M. McKeage, M. Reck, M. Jameson, M. Rosenthal, David Gibbs, P. Mainwaring, L. Freitag, R. Sullivan, J. Pawel (2009)
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.Lung cancer, 65 2
-
J. Hevmach, H. West, R. Kerr, D. Prager, A. Sandler, R. Herbst, D. Stewart, I. Dimery, B. Johnson (2005)
P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II studyLung Cancer, 49
-
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
-
(2007)
Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization -
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 366
-
Roy Herbst (2005)
Role of novel targeted therapies in the clinicBritish Journal of Cancer, 92
-
F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu (2005)
Erlotinib in previously treated non-small-cell lung cancerN Engl J Med, 353
-
H. Minami, K. Kawada, H. Ebi (2005)
A phase I study of BAY 43-9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancersProc Am Soc Clin Oncol, 23
-
S. Shukla, R. Robey, S. Bates, S. Ambudkar (2009)
Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2Drug Metabolism and Disposition, 37
-
(2005)
ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a twopart randomized phase II study -
M. Socinski, S. Novello, J. Brahmer, R. Rosell, J. Sánchez, C. Belani, R. Govindan, J. Atkins, H. Gillenwater, C. Pallarés, L. Tye, P. Selaru, R. Chao, G. Scagliotti (2008)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 4
-
M. Ruiz, K. Floor, Wim Vos, K. Grünberg, G. Meijer, Jose Rodriguez, G. Giaccone (2007)
Epidermal growth factor receptor (EGFR) gene copy number detection in non‐small‐cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridizationHistopathology, 51
-
A. Adjei, S. Mandrekar, R. Marks, L. Hanson, D. Aranguren, J. Jett, R. Simantov, B. Schwartz, G. Croghan (2005)
A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)Journal of Clinical Oncology, 23
-
(2009)
Phase II study of ASA404 (vadimezan, 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced nonsmall cell lung cancer -
M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. Albain, D. Cella, M. Wolf, S. Averbuch, J. Ochs, A. Kay (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA, 290 16
-
D. Mendel, A. Laird, Xiaohua Xin, S. Louie, J. Christensen, Guangmin Li, R. Schreck, T. Abrams, T. Ngai, Leslie Lee, Lesley Murray, J. Carver, E. Chan, K. Moss, J. Haznedar, J. Sukbuntherng, R. Blake, Li Sun, C. Tang, T. Miller, Sheri Shirazian, G. Mcmahon, J. Cherrington (2003)
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 1
-
R. Herbst, B. Johnson, J. Rowbottom, P. Fidias, Charles Lu, D. Prager, J. Roubec, E. Csada, I. Dimery, J. Heymach (2005)
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trialLung Cancer, 49
-
A. Jemal, Taylor Murray, Elizabeth Ward, A. Samuels, R. Tiwari, Asma Ghafoor, E. Feuer, M. Thun (2005)
Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 55
-
A. Ryan, S. Wedge (2005)
ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activityBritish Journal of Cancer, 92
-
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. Veneziani, G. Fontanini, A. Bianco, G. Tortora (2003)
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 4
-
J.R. Brahmer, C.P. Belani, R. Govindan (2007)
Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II studyJ Clin Oncol, 25
-
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
-
R.S. Herbst, B. Johnson, J. Rowbottom (2005)
ZD6474 plus docetaxel with previously treated NSCLC: results of a randomized, placebo-controlled phase II trialLung Cancer, 49
-
F. Ciardiello, R. Caputo, V. Damiano, R. Caputo, T. Troiani, D. Vitagliano, F. Carlomagno, B. Veneziani, G. Fontanini, A. Bianco, G. Tortora (2003)
Antitumor Effects of ZD 6474 , a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor , with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase 1 -
R. Natale, D. Bodkin, R. Govindan, B. Sleckman, N. Rizvi, A. Capó, P. Germonpré, I. Dimery, A. Webster, M. Ranson (2005)
O-103 A comparison of the antitumour efficacy of ZD6474 and gefitinib(Iressa™) in patients with NSCLC: Results of a randomized, double-blind Phase II studyLung Cancer, 49
-
H. Minami, K. Kawada, H. Ebi, K. Kitagawa, Y.-i. Kim, K. Araki, H. Mukai, M. Tahara, H. Nakajima, K. Nakajima (2005)
A phase I study of BAY 43–9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancersJournal of Clinical Oncology, 23
-
C. Cao, Chao Ji, A. Amaral, Avery Lee-Couture, N. Kouttab, Wen-ming Chu, W. Di, Y. Wan (2007)
EGFR tyrosine kinase activity is not necessary for ligand‐induced EGFR down‐regulation in ovarian cancer cellsThe FASEB Journal, 21
-
D. Kwiatkowski (2003)
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous SclerosisCancer Biology & Therapy, 2
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Tianjin Medical University Cancer Institute and Hospital and Springer Berlin Heidelberg
- Subject
- Medicine & Public Health; Oncology
- ISSN
- 1674-5361
- eISSN
- 1868-324X
- DOI
- 10.1007/s11805-011-0584-6
- Publisher site
- See Article on Publisher Site
Abstract
Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interfering at different stages to avoid cancer cell resistance to therapy. For this reason, new strategies for the simultaneous inhibition of multiple molecular targets are being pursued.
Journal
Clinical Oncology and Cancer Research – Springer Journals
Published: Dec 24, 2011